Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

References

• HortobagyiGNBlumenscheinGRSpanosWMultimodal treatment of locoregionally advanced breast cancerCancer19835157637686687377
   PubMed Web of Science ®Google Scholar
• HortobagyiGNAmesFCBuzdarAUManagement of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer19886212250725163056604
   PubMed Web of Science ®Google Scholar
• BearHDIndications for neoadjuvant chemotherapy for breast cancerSemin Oncol1998252 Suppl 3312
   Web of Science ®Google Scholar
• RastogiPAndersonSJBearHDPreoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27J Clin Oncol200826577878518258986
   PubMed Web of Science ®Google Scholar
• MauriDPavlidisNIoannidisJPNeoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysisJ Natl Cancer Inst200597318819415687361
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trialsLancet Oncol2018191273929242041
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar
• BurrisHYardleyDJonesSPhase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancerJ Clin Oncol20042291621162915117984
   PubMed Web of Science ®Google Scholar
• BuzdarAUIbrahimNKFrancisDSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol200523163676368515738535
   PubMed Web of Science ®Google Scholar
• BuzdarAUValeroVIbrahimNKNeoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimenClin Cancer Res200713122823317200359
   PubMed Web of Science ®Google Scholar
• BuzdarAUSumanVJMeric-BernstamFAmerican College of Surgeons Oncology Group investigatorsFluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastu-zumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialLancet Oncol201314131317132524239210
   PubMed Web of Science ®Google Scholar
• UntchMRezaiMLoiblSNeoadjuvant treatment with trastu-zumab in HER2-positive breast cancer: results from the GeparQuattro studyJ Clin Oncol201028122024203120308670
   PubMed Web of Science ®Google Scholar
• UntchMFaschingPAKonecnyGEPathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groupsJ Clin Oncol201129253351335721788566
   PubMed Web of Science ®Google Scholar
• YardenYBiology of HER2 and its importance in breast cancerOncology200161Suppl 2113
   PubMed Web of Science ®Google Scholar
• GhoshRNarasannaAWangSETrastuzumab has preferential activity against breast cancers driven by HER2 homodimersCancer Res20117151871188221324925
   PubMed Web of Science ®Google Scholar
• RimawiMFSchiffROsborneCKTargeting HER2 for the treatment of breast cancerAnnu Rev Med20156611112825587647
   PubMed Web of Science ®Google Scholar
• RexerBNArteagaCLIntrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implicationsCrit Rev Oncog201217111622471661
   PubMedGoogle Scholar
• RimawiMFde AngelisCSchiffRResistance to anti-HER2 therapies in breast cancerAm Soc Clin Oncol Educ Book201535e157e164
   Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYH5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLancet Oncol201617679180027179402
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHickishTPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Ann Oncol20132492278228423704196
   PubMed Web of Science ®Google Scholar
• UntchMJackischCSchneeweissAGerman Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) InvestigatorsNab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trialLancet Oncol201617334535626869049
   PubMed Web of Science ®Google Scholar
• HurvitzSASymmansWFJungKHHuangC-SThompsonAMPathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE)J Clin Oncol2016500500
   Web of Science ®Google Scholar
• Ulrike NitzOGChristgenMGrischkeE-MAugustinDKümmelSFinal analysis of WSG-ADAPT HER2+/HR− trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR− early breast cancer (EBC)J Clin Oncol2016518518
   Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• de AzambujaEHolmesAPPiccart-GebhartMLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseLancet Oncol201415101137114625130998
   PubMed Web of Science ®Google Scholar
• GuarneriVFrassoldatiABottiniAPreoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB studyJ Clin Oncol201230161989199522493419
   PubMed Web of Science ®Google Scholar
• UntchMLoiblSBischoffJGerman Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study GroupLapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialLancet Oncol201213213514422257523
   PubMed Web of Science ®Google Scholar
• CareyLAClinical and translational results of CALGB 40601: A neo-adjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancerJ Clin Oncol2013500500
   Google Scholar
• EllisPSmithIAshleySClinical prognostic and predictive factors for primary chemotherapy in operable breast cancerJ Clin Oncol19981611071149440730
   PubMed Web of Science ®Google Scholar
• ChangJPowlesTJAllredDCBiologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancerJ Clin Oncol199917103058306310506600
   PubMed Web of Science ®Google Scholar
• PusztaiLGianniLTechnology insight: emerging techniques to predict response to preoperative chemotherapy in breast cancerNat Clin Pract Oncol200411445016264799
   PubMedGoogle Scholar
• VinnicombeSJMacVicarADGuyRLPrimary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlationRadiology199619823333408596827
   PubMed Web of Science ®Google Scholar
• HerradaJIyerRBAtkinsonENSneigeNBuzdarAUHortobagyiGNRelative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinomaClin Cancer Res199739156515699815844
   PubMed Web of Science ®Google Scholar
• MartincichLMontemurroFde RosaGMonitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imagingBreast Cancer Res Treat2004831677614997056
   PubMed Web of Science ®Google Scholar
• ChenJHBahriSMehtaRSBreast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imagingRadiology2011261373574321878615
   PubMed Web of Science ®Google Scholar
• ChenJHSuMYClinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapyBiomed Res Int20132013234816723862143
   PubMed Web of Science ®Google Scholar
• WoolfDKPadhaniARMakrisAMagnetic resonance imaging, digital mammography, and sonography: tumor characteristics and tumor biology in primary settingJ Natl Cancer Inst Monogr2015201551152026063879
   PubMedGoogle Scholar
• ChenJHFeigBAgrawalGMRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapyCancer20081121172618000804
   PubMed Web of Science ®Google Scholar
• BroglioKRQuintanaMFosterMAssociation of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysisJAMA Oncol201626E1E10
   Web of Science ®Google Scholar
• von MinckwitzGFontanellaCComprehensive review on the surrogate endpoints of efficacy proposed or hypothesized in the scientific community todayJ Natl Cancer Inst Monogr2015201551293126063882
   PubMedGoogle Scholar
• Wang-LopezQChalabiNAbrialCCan pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?Crit Rev Oncol Hematol20159518810425900915
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• Tan-ChiuEYothersGRomondEAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31J Clin Oncol200523317811781916258083
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol20082681231123818250349
   PubMed Web of Science ®Google Scholar
• BatistGBartonJChaikinPSwensonCWellesLMyocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapyExpert Opin Pharmacother20023121739175112472371
   PubMedGoogle Scholar
• GaviláJGuerreroÁClimentMÁEfficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practiceInt J Clin Oncol201520348048925011497
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology; College of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
   PubMed Web of Science ®Google Scholar
• WolffACHammondMEHicksDGAmerican Society of Clinical Oncology; College of American PathologistsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateArch Pathol Lab Med2014138224125624099077
   PubMed Web of Science ®Google Scholar
• KuehnTBauerfeindIFehmTSentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort studyLancet Oncol201314760961823683750
   PubMed Web of Science ®Google Scholar
• BougheyJCSumanVJMittendorfEAAlliance for Clinical Trials in OncologySentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the American College of Surgeons Oncology Group (ACOSOG) Z1071 clinical trialJAMA2013310141455146124101169
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEAGwyther new guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• OgstonKNMillerIDPayneSA new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survivalBreast200312532032714659147
   PubMed Web of Science ®Google Scholar
• CareyLAMetzgerRDeesECAmerican joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcomeJ Natl Cancer Inst200597151137114216077072
   PubMedGoogle Scholar
• GargAKStromEAMcNeeseMDT3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapyInt J Radiat Oncol Biol Phys200459113814515093909
   PubMed Web of Science ®Google Scholar
• HuangEHTuckerSLStromEAPostmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomyJ Clin Oncol200422234691469915570071
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsCancer200397112869287912767102
   PubMed Web of Science ®Google Scholar
• TsaiHTIsaacsCFuAZRisk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based studyBreast Cancer Res Treat2014144116317024469642
   PubMed Web of Science ®Google Scholar
• DranitsarisGRaysonDVincentMThe development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclinesBreast Cancer Res Treat2008107344345017978870
   PubMed Web of Science ®Google Scholar
• FumoleauPRochéHKerbratPFrench Adjuvant Study GroupLong-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group resultsAnn Oncol2006171859216251204
   PubMed Web of Science ®Google Scholar
• SciarrettaSPalanoFTocciGBaldiniRVolpeMAntihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular riskArch Intern Med2011171538439421059964
   PubMedGoogle Scholar
• CarverJRShapiroCLNgAASCO Cancer Survivorship Expert PanelAmerican Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effectsJ Clin Oncol200725253991400817577017
   PubMed Web of Science ®Google Scholar
• GroarkeJDNguyenPLNohriaAFerrariRChengSMoslehiJCardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular diseaseEur Heart J2014351061262323666251
   PubMed Web of Science ®Google Scholar
• AntónARuizAPlazaolaAPhase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 studyAnn Oncol2011221747920603435
   PubMed Web of Science ®Google Scholar
• TuxenMKColdSTangeUBBalslevENielsenDLPhase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancerActa Oncol201453101440144524991893
   PubMed Web of Science ®Google Scholar
• Uriarte-PintoMEscolano-PueyoÁGimeno-BallesterVPascual-MartínezOAbad-SazatornilMRAgustín-FerrándezMJTrastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancerInt J Clin Pharm2016362446453
   Web of Science ®Google Scholar
• CareyLABerryDACirrincioneCTMolecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinibJ Clin Oncol201634654254926527775
   PubMed Web of Science ®Google Scholar
• YerushalmiRWoodsRRavdinPMHayesMMGelmonKAKi67 in breast cancer: prognostic and predictive potentialLancet Oncol201011217418320152769
   PubMed Web of Science ®Google Scholar
• DowsettMNielsenTOA’HernRInternational Ki-67 in Breast Cancer Working GroupAssessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupJ Natl Cancer Inst2011103221656166421960707
   PubMed Web of Science ®Google Scholar
• TashimaRNishimuraROsakoTEvaluation of an optimal cutoff point for the Ki-67 index as a prognostic factor in primary breast cancer: a retrospective studyPLoS One2015157e0119565
   Google Scholar
• WolffBHistological grading in carcinoma of the breastBr J Cancer196620136405937523
   PubMed Web of Science ®Google Scholar
• FisherERSassRFisherBPathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failureCancer1984533 Suppl7127236692274
   PubMed Web of Science ®Google Scholar
• ContessoGMouriesseHFriedmanSGeninJSarrazinDRouesseJThe importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-RoussyJ Clin Oncol198759137813863625256
   PubMed Web of Science ®Google Scholar
• ElstonCWEllisIOPathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-upHistopathology19911954034101757079
   PubMed Web of Science ®Google Scholar
• GaleaMHBlameyRWElstonCEEllisIOThe Nottingham Prognostic Index in primary breast cancerBreast Cancer Res Treat19922232072191391987
   PubMed Web of Science ®Google Scholar
• DabbsDJDuctal carcinoma of breast: nuclear grade as a predictor of S-phase fractionHum Pathol19932466526568389317
   PubMed Web of Science ®Google Scholar
• FisherBBrownAMamounasEEffect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18J Clin Oncol1997157248324939215816
   PubMed Web of Science ®Google Scholar
• WolmarkNWangJMamounasEBryantJFisherBPreoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18J Natl Cancer Inst Monogr200120013096102
   Google Scholar
• van der HageJAvan de VeldeCJJulienJPTubiana-HulinMVanderveldenCDuchateauLPreoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902J Clin Oncol200119224224423711709566
   PubMed Web of Science ®Google Scholar
• MieogJSvan der HageJAvan de VeldeCJNeoadjuvant chemotherapy for operable breast cancerBr J Surg200794101189120017701939
   PubMed Web of Science ®Google Scholar
• ChenAMMeric-BernstamFHuntKKBreast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experienceJ Clin Oncol200422122303231215197191
   PubMed Web of Science ®Google Scholar
• ChenAMMeric-BernstamFHuntKKBreast conservation after neoadjuvant chemotherapyCancer2005103468969515641036
   PubMed Web of Science ®Google Scholar
• LobbesMBIPrevosRSmidtMThe role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewInsights Imaging20134216317523359240
   PubMedGoogle Scholar
• MarinovichMLHoussamiNMacaskillPMeta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapyJ Natl Cancer Inst2013105532133323297042
   PubMedGoogle Scholar
• ThavendiranathanPPoulinFLimKDPlanaJCWooAMarwickTHUse of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic reviewJ Am Coll Cardiol20146325 Pt A2751276824703918
   PubMed Web of Science ®Google Scholar
• MehtaLSWatsonKEBaracAAmerican Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes ResearchCardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the american heart associationCirculation20181378e30e6629437116
   PubMed Web of Science ®Google Scholar
• CardinaleDColomboATorrisiRTrastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluationJ Clin Oncol201028253910391620679614
   PubMed Web of Science ®Google Scholar
• PondeNBradburyILambertiniMCardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)Breast Cancer Res Treat2018168363163829280043
   PubMed Web of Science ®Google Scholar
• AmmonMArenjaNLeibundgutGCardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practiceJ Card Fail201319962963424054339
   PubMed Web of Science ®Google Scholar
• OliveiraGHMukerjiSHernandezAVIncidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patientsAm J Cardiol2014113111893189824837270
   PubMed Web of Science ®Google Scholar
• CuevaJFAntolínSCalvoLGalician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention an early interventionClin Trasl Oncol201719910671078
   Web of Science ®Google Scholar